Dainippon Sumitomo Pharma Co., Ltd. Company Profile

News Articles [ 1315 Associated News Articles listed on BioPortfolio]

Dainippon Sumitomo

Dainippon Sumitomo is a top pharmaceutical company based in Osaka, Japan. The company was formed as a merger between Dainippon Pharmaceuticals and Sumitomo Pharmaceuticals on October 1st 2005. Dainipp...

Dainippon Sumitomo partners with Nippon Shinyaku for urology drug AMP-986

Japanese drugmakers Dainippon Sumitomo Pharma (TYO: 4506) and Nippon Shinyaku (TYO: 4516) have concluded a license agreement for exclusive rights to develop, manufacture and commercialize SMP-986 in J...

Dainippon Sumitomo pharma partners with Edison for EPI-743 and EPI-589

Edison Pharmaceuticals pharma partners with Dainippon Sumitomo, a big pharma company in a  research/development and commercialization agreement with  for the development of EPI-743 and EPI-589 in J...

Dainippon Sumitomo to set up DSP Cancer Institute

Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) says it plans to establish a new organization specializing in the oncology area to be called the DSP Cancer Institute and also announced organ...

Dainippon Sumitomo Pharma Q1 Net Income Decreases

From Datamonitor (October 3, 2012) Oct 03, 2012 (Datamonitor via COMTEX) -- Dainippon Sumitomo Pharma Co. Ltd. has reported that net income for the first quarter ended June 30, 2012 was JPY5.7 billion...

Kobe University, KNC Laboratories and Dainippon Sumitomo Pharma in Joint-research for Anti-cancer Compound

Kobe University, KNC Laboratories and Dainippon Sumitomo Pharma Co., Ltd. have announced the signing of an exclusive world-wide license agreement for the development, manufacturing and sales of promis...

Dainippon Sumitomo gains rights to Edison Pharma drug candidates in up to $545 million accord

Privately-held US firm Edison Pharmaceuticals has entered into a research, development and commercialization agreement with Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506)) for the developme...

Dainippon Sumitomo on the Ras as it locks in cancer candidates from Kobe partners

Dainippon Sumitomo Pharma (DSP) is continuing its push to build up in-house R&D in the oncology area through a new agreement with two partners in Japan for small molecule Ras inhibitors. The firm has...

Drugs and Medications [ 238 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

Metoprolol tartrate [Med-Health Pharma, LLC]

Metoprolol Tartrate Tablets, USP

Urea [Libertas Pharma, Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

PubMed Articles [ 84 Associated PubMed Articles listed on BioPortfolio]

Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.

Structures containing the (R)-3-amino-3-methyl piperidine unit as a new pharmacophore moiety have been shown to possess moderate inhibitory activity for DPP-4 with good pharmacokinetics profile. One o...

Mitochondrial {gamma}-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein.

Intracellular amyloid-β peptide (Aβ) has been implicated in the pathogenesis of Alzheimer`s disease (AD). Mitochondria were found to be the target both for amyloid precursor protein (APP) that accum...

A new methodology for simultaneous quantification of total-Aβ, Aβx-38, Aβx-40, and Aβx-42 by column-switching LC/MS/MS.

This article details the development of a novel method that overcomes the drawbacks of sandwich ELISA (sELISA) and allows reliable evaluation of simultaneous quantification of the amyloid (Aβ)-peptid...

2-({6-(3R)-3-amino-3-methylpiperidine-1-yl-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo3,2-dpyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): A potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of

We report on the identification of 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727) (7a)...

Intra-tracheal and oral administration of SM-276001, a selective TLR7 agonist, leads to anti-tumour efficacy in primary and metastatic models of cancer.

Topical TLR7 agonists such as imiquimod are highly effective for the treatment of dermatological malignancies however their efficacy in the treatment of non-dermatological tumours has been less succes...

Clinical Trials [ 35 Associated Clinical Trials listed on BioPortfolio]

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

This is 2-armed parallel group, prospective, randomized, open-label, multicenter Phase 3 controlled trial to establish the efficacy and safety of conversion from maintenance immunosuppress...

Development of a New Method for Analgesia

Aim: To examine a new method to perform local anesthesia in order to diminish the inconvenience by the procedure in patients before performing intubation or oesophagogastroduodenoscopy.

Companies [ 595 Associated Companies listed on BioPortfolio]

Dainippon Sumitomo Pharma Co., Ltd.

Dainippon Sumitomo Pharma Co., Ltd., (DSP), is a top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical, animal health and food and specialty products. DSP's strong...

Dainippon Sumitomo Pharma America, Inc.

Dainippon Sumitomo Pharma America, Inc. (DSPA) located in Fort Lee, N.J., is a subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP). On April 1, 2010, DSP's two North American operations - DSPA and...

Sumitomo Corporation Europe Limited

Sumitomo Corporation Europe is a principal subsidiary of Sumitomo Corporation, a leading integrated trading company with its headquarters in Japan, and as such we share in its key role in the exchange...

Sumitomo Corporation of America

Sumitomo Corporation of America (SCOA) is a wholly owned subsidiary of Sumitomo Corporation (SC), an integrated trading and investment enterprise engaged in multifaceted business activities, which inc...

Sepracor Inc.

Sepracor Inc., an indirect, wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd., is a research-based pharmaceutical company dedicated to treating and preventing human d...